<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950547</url>
  </required_header>
  <id_info>
    <org_study_id>00-02</org_study_id>
    <nct_id>NCT00950547</nct_id>
  </id_info>
  <brief_title>ICU Cell Saver to Reduce Blood Transfusions in Cardiac</brief_title>
  <official_title>Routinely Use of CardioPAT Cell Saver in Cardiac Surgery: A Prospective Randomized Study Focused on Allogenic Blood Transfusion and Clinical Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiochirurgia E.H.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiochirurgia E.H.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE: Autotransfusion devices may be employed in cardiac surgery to decrease allogenic
      blood requirements. Limitations of previous trials include the use of cell saver systems in
      selected high risk patients only or the lack of blood transfusion-sparing strategies. The aim
      of this prospective randomized study is to evaluate the efficacy of cell salvage CardioPAT
      routinely used in cardiac surgery.

      METHODS: The investigators will randomize 350 patients in two groups: group 1 receives a
      CardioPAT cell saver device (175 patients), group 2 doesn't receive any cell saver device.
      The incidence of allogenic blood transfusion and clinical outcome in both groups are
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Transfusions per patient</measure>
    <time_frame>10 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Blood Transfusion</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional Chest drains</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CARDIOPAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CARDIOPAT Cell Saver after Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CARDIOPAT</intervention_name>
    <description>Cell Saver System at bedside for ICU stay</description>
    <arm_group_label>CARDIOPAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Traditional Chest Drains</intervention_name>
    <description>Chest drains as usual with no possibility to reinfuse lost blood</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting for cardiac Surgery

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiochirurgia European Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2009</study_first_posted>
  <last_update_submitted>January 4, 2010</last_update_submitted>
  <last_update_submitted_qc>January 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Saverio Nardella</name_title>
    <organization>Cardiochirurgia E.H.</organization>
  </responsible_party>
  <keyword>Blood Transfusion</keyword>
  <keyword>Cell Saver</keyword>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Evaluate the efficacy of cell salvage CardioPAT routinely used in cardiac surgery in reducing blood transfusions.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

